PMID: 19916336Nov 18, 2009Paper

Live xenogenic vaccine in the prevention of metastases of uveal melanoma

Vestnik oftalmologii
A F BrovkinaT V Barannikova

Abstract

By the results of experimental studies and by being guided by Protocol No. 22 dated January 22, 2004, by the Ministry of Health of the Russian Federation, the authors have conducted clinical trials of biotherapy used in oncological care. They describe the first experience in using xenovaccination in 35 patients with uveal melanoma to prevent hematogenic metastases. The follow-ups of the patients lasted within 14-49 months after initiation of the vaccination. No recurrences were observed in 30 patients during follow-ups whose durations averaged 41.3 months. The authors consider that this is reason to regard xenovaccination as an available method for the prevention of metastases of uveal melanoma.

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

Current Opinion in Allergy and Clinical Immunology
Mikael Kuitunen
Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
Noriyoshi SawabataJapanese Joint Committee for Lung Cancer Registration
© 2022 Meta ULC. All rights reserved